While German Nasdaq company Affimed (AFMD) had an accumulated loss of over €100m, an annual development cost of about €38m for its Tandab pipeline, and an income of only about €8m from collaborations at the end of 2015, the company is trying to bulk up its funds through a public offering of common stock.
Will the Trump effect last?
OpinionThe surprising election of Donald Trump as the next US President led to a spectacular comeback of biotech shares. The long-term prospects depend on Trump’s healthcare strategy and the (much-desired) return of generalist funds.
GM mosquitoes to be released in India
Latest NewsOxford-based Intrexion-subsidiary Oxitec plans to release male GM mosquitoes that produce nonviable offspring in India, in order to limit the spread of dengue and chikungunya fevers transmitted by Aedes aegyptii.
Biotech CEOs advise EU on breakthrough innovations
Latest NewsTwo biotech CEOs have been selected by the European Commission for the High Level Group. The EU think tank will provide strategic input to Horizon 2020 and a €2.5bn fund to support innovation by 2020 in order to boost disruptive technologies and to address gaps in in the current innovation support landscape.
Affimed is seeking funds
Latest NewsWhile German Nasdaq company Affimed (AFMD) had an accumulated loss of over €100m, an annual development cost of about €38m for its Tandab pipeline, and an income of only about €8m from collaborations at the end of 2015, the company is trying to bulk up its funds through a public offering of common stock.
Eppendorf: Veteran supervisor
AppointmentsPromega-founder William Linton has been elected as a member of the Supervisory Board of lab supplier Eppendorf AG.
Octimet bags €11m for development of cancer drugs
Latest NewsBelgian start-up company Octimet Oncology NV has secured €11.3m in a series A financing round. The funds will be used to develop two MET kinase blockers to treat solid tumours.
Joint-venture Fibrocor tackles fibrosis
Latest NewsDrug screening expert Evotec AG and Ontario-based MaRS Innovation have launched the joint venture company Fibrocor Therapeutics LP to tackle fibrosis, an unmet medical need and multi-billion US dollars market.
Ixico: Taking over from the founder
AppointmentsNew technology speeds up mapping of DNA-protein interaction
Latest NewsScientists at EPFL have developed a technique that can be a game-changer for genetics by making the characterisation of DNA-binding proteins much faster, more accurate, and efficient.
Telix licenses Wilex’ girentuximab programme
Latest NewsGerman Wilex has licensed its clear cell renal cell carcinoma (ccRCC) antibody Redectane to Australian biopharma company Telix Pharmaceuticals. Redectane is a radiolabeled version of Wilex’ Phase III therapeutic antibody girentuximab.